Experience
Rubrik Announces $752 Million Upsized IPO
April 29, 2024
Cooley advised Rubrik, the Zero Trust Data Security Company delivering data security and operational resilience for enterprises, on its $752 million initial public offering. Rubrik issued and sold 23,500,000 shares of Class A common stock priced at $32 per share, with a 30-day option for the underwriters to purchase up to 3,525,000 additional shares of Class A common stock.
Related contacts
Related Practices & Industries
ProfoundBio Announces $1.8 Billion Acquisition by Genmab
April 3, 2024
Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.
Related contacts
Related Practices & Industries
Blue Owl Capital Invests up to $1.05 Billion in BridgeBio Pharma
January 17, 2024
Cooley advised Blue Owl Capital, a top asset manager redefining alternatives, on its strategic investment a $300 million royalty financing and a $450 million credit facility in BridgeBio Pharma, a commercial-stage biopharmaceutical company focused on genetic diseases and cancers.
Related contacts
Related Practices & Industries
MadCap Software Acquires Xyleme
January 11, 2024
Cooley advised MadCap Software, a multichannel content authoring, management and publishing solutions provider, on its acquisition of Xyleme, which offers intelligent content management for the development, control, delivery, and syndication of vital proprietary learning and development content across the enterprise.
Related contacts
Related Practices & Industries
Carmot Therapeutics Enters Definitive Merger Agreement With Roche
December 3, 2023
Cooley advised Carmot Therapeutics, a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, on its definitive merger agreement in which Roche will acquire Carmot.
Related contacts
Related Practices & Industries
Related news and events
Admissions & credentials
District of Columbia
New York